NCT05857735

Brief Summary

Acute coronary syndrome (ACS) is the most common presentation of Coronary Artery Disease (CAD). It causes significant morbidity and mortality. The Gulf Registry of Acute Coronary Events (Gulf RACE) was conducted in 2007 and filled a wide gap in our understanding of ACS and its management in Kuwait and the Arabian Gulf region. However, the management of ACS has undergone tremendous advances over the last two decades involving pharmacotherapy and device therapy. Practice guidelines have also changed over the last decade. For example, in 2007, there was no catheterization laboratory in any of the general hospitals in Kuwait, primary percutaneous coronary intervention (PCI) was not being practiced, and the rate of in-hospital cardiac catheterization for all ACS patients was very low at around 10%. Currently, of the eight general hospitals in Kuwait, six have catheterization laboratories and five of the six serve as primary PCI centers. There is no contemporary ACS registry in Kuwait, studying its incidence, management, and influence of current changes in clinical practice on patients' outcomes. This multicentre disease-based, country-wide registry is guided by the American Heart Association policy statement for expanding the applications of existing and future clinical registries and the User's Guide published by the Agency for Health care Research and Quality guidance.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,812

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 2, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

May 15, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

May 15, 2023

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 25, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

August 20, 2025

Status Verified

March 1, 2025

Enrollment Period

1.5 years

First QC Date

May 2, 2023

Last Update Submit

August 19, 2025

Conditions

Keywords

MortalityInhospital MACE30-day MACE

Outcome Measures

Primary Outcomes (2)

  • Mortality

    To measure the adverse outcome of in-hospital mortality in ACS patients in Kuwait.

    through study completion, an average of 6 months

  • Major Adverse Cardiac Events (MACE)

    To measure the in-hospital adverse outcomes like myocardial infarction (MI), cerebrovascular accident (CVA), bleeding, cardiogenic shock, heart failure and others in ACS patients in Kuwait.

    through study completion, an average of 6 months

Secondary Outcomes (6)

  • Mortality

    30 days from discharge

  • Major Adverse Cardiac Events (MACE)

    30 days from discharge

  • Rehospitalization

    within 30 days from discharge

  • Revascularization

    within 30 days from discharge

  • Lipid level control

    At 6 months from ACS event

  • +1 more secondary outcomes

Study Arms (1)

ACS patients

Patients admitted to hospital with diagnosis of ACS.

Other: Observational registry with no intervention.

Interventions

No intervention

ACS patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients who are admitted to any of the eight general hospitals in Kuwait with a diagnosis of ACS. The sample size will be 10,000 patients. ACS diagnosis includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina.

You may qualify if:

  • Patient is admitted to hospital with admission diagnosis of ACS.
  • Patient or a relative consent to enrolment in the registry.

You may not qualify if:

  • Refusal or inability to consent for enrolment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mubarak Al Kabeer hospital

Kuwait City, Kuwait, 13110, Kuwait

Location

Study Officials

  • Mohammad Zubaid, Professor

    Kuwait University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 2, 2023

First Posted

May 15, 2023

Study Start

May 15, 2023

Primary Completion

November 25, 2024

Study Completion

June 30, 2025

Last Updated

August 20, 2025

Record last verified: 2025-03

Locations